Stuart Rich

33.3k total citations · 9 hit papers
183 papers, 23.1k citations indexed

About

Stuart Rich is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Stuart Rich has authored 183 papers receiving a total of 23.1k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Pulmonary and Respiratory Medicine, 108 papers in Cardiology and Cardiovascular Medicine and 24 papers in Surgery. Recurrent topics in Stuart Rich's work include Pulmonary Hypertension Research and Treatments (137 papers), Cardiovascular Function and Risk Factors (40 papers) and Cardiovascular Issues in Pregnancy (40 papers). Stuart Rich is often cited by papers focused on Pulmonary Hypertension Research and Treatments (137 papers), Cardiovascular Function and Risk Factors (40 papers) and Cardiovascular Issues in Pregnancy (40 papers). Stuart Rich collaborates with scholars based in United States, Canada and United Kingdom. Stuart Rich's co-authors include Vallerie V. McLaughlin, Bruce H. Brundage, Elizabeth Kaufmann, Robyn J. Barst, P. S. Levy, Stephen L. Archer, Lewis J. Rubin, Mardi Gomberg‐Maitland, Alicia C. Shillington and Gérald Simonneau and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Stuart Rich

179 papers receiving 22.2k citations

Hit Papers

Survival in Patients with... 1987 2026 2000 2013 1991 1996 1987 2004 1992 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Survival in Patients with Primary Pulmonary Hypertension
    1991 2.6k citations Gilbert E. D’Alonzo, Robyn J. Barst et al. Annals of Internal Medicine profile →
  2. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
    1996 2.0k citations Robyn J. Barst, Lewis J. Rubin et al. profile →
  3. Primary Pulmonary Hypertension
    1987 1.5k citations Stuart Rich et al. Annals of Internal Medicine profile →
  4. Clinical classification of pulmonary hypertension
    2004 1.3k citations Gérald Simonneau, Nazzareno Galiè et al. Journal of the American College of Cardiology profile →
  5. The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
    1992 1.1k citations Stuart Rich et al. profile →
  6. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial
    2002 1.1k citations Gérald Simonneau, Robyn J. Barst et al. American Journal of Respiratory and Critical Care Medicine profile →
  7. Survival in Primary Pulmonary Hypertension
    2002 902 citations Vallerie V. McLaughlin, Stuart Rich et al. Circulation profile →
  8. Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
    1996 813 citations Yola Moride, Stuart Rich et al. profile →
  9. Pulmonary Arterial Hypertension
    2013 378 citations Michael D. McGoon, Raymond L. Benza et al. Journal of the American College of Cardiology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stuart Rich 19.2k 14.3k 3.7k 3.1k 2.3k 183 23.1k
Michael D. McGoon 22.6k 1.2× 18.2k 1.3× 3.8k 1.0× 4.3k 1.4× 2.6k 1.1× 176 28.5k
Robert Naeije 17.8k 0.9× 13.8k 1.0× 1.8k 0.5× 3.0k 1.0× 1.4k 0.6× 464 23.0k
Marius M. Hoeper 22.0k 1.1× 14.7k 1.0× 3.8k 1.0× 4.0k 1.3× 2.5k 1.1× 464 27.0k
Vallerie V. McLaughlin 19.4k 1.0× 13.5k 0.9× 3.7k 1.0× 2.1k 0.7× 2.2k 0.9× 273 21.5k
Nazzareno Galiè 24.2k 1.3× 17.4k 1.2× 4.7k 1.3× 2.6k 0.8× 2.6k 1.1× 409 27.7k
Horst Olschewski 17.2k 0.9× 10.3k 0.7× 2.4k 0.7× 2.1k 0.7× 1.5k 0.6× 334 21.3k
David B. Badesch 23.3k 1.2× 15.2k 1.1× 4.5k 1.2× 3.0k 1.0× 3.0k 1.3× 180 25.9k
Iréne Lang 11.7k 0.6× 12.3k 0.9× 2.4k 0.7× 3.3k 1.1× 788 0.3× 527 20.4k
Robyn J. Barst 30.6k 1.6× 21.2k 1.5× 6.6k 1.8× 4.0k 1.3× 3.5k 1.5× 250 34.2k
Olivier Sitbon 24.9k 1.3× 14.8k 1.0× 5.4k 1.5× 3.5k 1.1× 3.6k 1.6× 460 27.7k

Countries citing papers authored by Stuart Rich

Since Specialization
Citations

This map shows the geographic impact of Stuart Rich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Rich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Rich more than expected).

Fields of papers citing papers by Stuart Rich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Rich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Rich. The network helps show where Stuart Rich may publish in the future.

Co-authorship network of co-authors of Stuart Rich

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Rich. A scholar is included among the top collaborators of Stuart Rich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Rich. Stuart Rich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fudim, Marat, David M. Kaye, Barry A. Borlaug, et al.. (2022). Venous Tone and Stressed Blood Volume in Heart Failure. Journal of the American College of Cardiology. 79(18). 1858–1869. 51 indexed citations
2.
Emmons‐Bell, Sophia, Catherine O. Johnson, Paul A. Corris, et al.. (2021). Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. Pulmonary Circulation. 12(1). e12020–e12020. 33 indexed citations
3.
Brener, Michael I., Nadira Hamid, Kenji Sunagawa, et al.. (2021). Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action From the HELP Trial. Journal of Cardiac Failure. 27(9). 1023–1026. 11 indexed citations
4.
Burkhoff, Daniel, Stuart Rich, Piero Pollesello, & Zoltán Papp. (2021). Levosimendan-Induced Venodilation is Mediated by Opening of Potassium Channels. ESC Heart Failure. 8(6). 4454–4464. 15 indexed citations
5.
D’Alonzo, Gilbert E., Robyn J. Barst, Stephen M. Ayres, et al.. (2020). Survival in Patients with Primary Pulmonary Hypertension. Annals of Internal Medicine. 3 indexed citations
6.
Wax, David, et al.. (2019). Novel shunt modification with an adjustable stent‐embedded “fenestrated” septal occluder in a patient with pulmonary hypertension. Catheterization and Cardiovascular Interventions. 93(7). 1382–1384. 1 indexed citations
7.
Meduri, Christopher, Charles J. Davidson, Scott Lim, et al.. (2018). 30 DAY RESULTS OF THE SCOUT I STUDY IN PATIENTS WITH SEVERE TRICUSPID REGURGITATION (TR). Journal of the American College of Cardiology. 71(11). A1004–A1004. 1 indexed citations
8.
Hemnes, Anna R., Aaron W. Trammell, Stephen L. Archer, et al.. (2014). Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. Circulation. 131(4). 401–409. 59 indexed citations
9.
Ryan, John, Thenappan Thenappan, Nancy Luo, et al.. (2012). The WHO Classification of Pulmonary Hypertension: A Case‐Based Imaging Compendium. Pulmonary Circulation. 2(1). 107–121. 38 indexed citations
10.
Thenappan, Thenappan, Sanjiv J. Shah, Stuart Rich, et al.. (2009). Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. European Respiratory Journal. 35(5). 1079–1087. 360 indexed citations
11.
Elliott, C. Gregory, Eric W. Glissmeyer, John F. Carlquist, et al.. (2006). Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension. Circulation. 113(21). 2509–2515. 110 indexed citations
12.
McLaughlin, Vallerie V., Robyn J. Barst, Mardi Gomberg‐Maitland, et al.. (2005). ONE YEAR EXPERIENCE WITH INTRAVENOUS TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS. CHEST Journal. 128(4). 160S–160S. 3 indexed citations
13.
McLaughlin, Vallerie V., Seán Gaine, Robyn J. Barst, et al.. (2003). Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology. 41(2). 293–299. 176 indexed citations
14.
Barst, Robyn J., et al.. (2003). Sitaxsentan in Pulmonary Arterial Hypertension. CHEST Journal. 123(5). 1772–1773. 1 indexed citations
15.
Simonneau, Gérald, Robyn J. Barst, Nazzareno Galiè, et al.. (2002). Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine. 165(6). 800–804. 1052 indexed citations breakdown →
16.
Rich, Stuart, et al.. (1998). Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. Pneumologie. 52(4). 238–239. 21 indexed citations
17.
Abenhaim, Lucien, Yola Moride, F Brénot, et al.. (1997). Appetite-suppressant drugs and the risk of primary pulmonary hypertension. Pneumologie. 51(10). 7 indexed citations
18.
Rich, Stuart. (1995). Calcium channel blockers for the treatment of primary pulmonary hypertension. European Respiratory Review. 5(29). 252–254. 4 indexed citations
19.
Giles, Thomas D., Richard J. Katz, Jay M. Sullivan, et al.. (1989). Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. Journal of the American College of Cardiology. 13(6). 1240–1247. 95 indexed citations
20.
Louie, Eric K., Stuart Rich, & Bruce H. Brundage. (1986). Doppler echocardiography assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension. Journal of the American College of Cardiology. 8(6). 1298–1306. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael D. McGoon Breakdown of academic impact, for papers by Robert Naeije Breakdown of academic impact, for papers by Marius M. Hoeper Breakdown of academic impact, for papers by Vallerie V. McLaughlin Breakdown of academic impact, for papers by Nazzareno Galiè Breakdown of academic impact, for papers by Horst Olschewski Breakdown of academic impact, for papers by David B. Badesch Breakdown of academic impact, for papers by Iréne Lang Breakdown of academic impact, for papers by Robyn J. Barst Breakdown of academic impact, for papers by Olivier Sitbon
Rankless by CCL
2026